|
1
|
Ye T, Ma L and Luo S: Advances in the
treatment of acute lymphoblastic leukemiaProceedings of the Fifth
National Anatomy and Technology Conference. Three Gorges
University; Fuzhou: pp. 301–302. 2015
|
|
2
|
Zheng HY: Advancement of treatment of
acute lymphoblastic leukemia in children. J Appl Clin Pediat.
22:167–169. 2007.
|
|
3
|
Pui CH, Mullighan CG, Evans WE and Relling
MV: Pediatric acute lymphoblastic leukemia: Where are we going and
how do we get there? Blood. 120:1165–1174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hunger SP, Loh ML, Whitlock JA, Winick NJ,
Carroll WL, Devidas M and Raetz EA: COG Acute Lymphoblastic
Leukemia Committee: Children's Oncology Group's 2013 blueprint for
research: Acute lymphoblastic leukemia. Pediatr Blood Cancer.
60:957–963. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun Q, Tang J and Huang MY: Advancement of
treatment plan of acute lymphoblastic leukemia in children. Med
Inform. 28:389. 2015.
|
|
6
|
Hu YY and Ge FM: Advancement of treatment
of acute lymphoblastic leukemia in adult. J Pract Oncol.
29:591–594. 2014.
|
|
7
|
Linker CA, Levitt LJ, O'Donnell M, Forman
SJ and Ries CA: Treatment of adult acute lymphoblastic leukemia
with intensive cyclical chemotherapy: A follow-up report. Blood.
78:2814–2822. 1991.PubMed/NCBI
|
|
8
|
Zhang QG, Xie ST, Zeng QF, Xiao Y and Liu
X: Effect and toxic and side effects of TBI treating refractory
lymphoma in APBSCT. Contemp Med. 34:1–3. 2014.
|
|
9
|
Kim I, Park S, Kim BK, Chang HM, Bang SM,
Byun JH, Kim DJ, Min WS, Kim HJ and Kim CC: Allogeneic bone marrow
transplantation for chronic myeloid leukemia: A retrospective study
of busulfan-cytoxan versus total body irradiation-cytoxan as
preparative regimen in Koreans. Clin Transplant. 15:167–172. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakasone H, Fukuda T, Kanda J, Mori T,
Yano S, Kobayashi T, Miyamura K, Eto T, Kanamori H, Iwato K, et al:
Impact of conditioning intensity and TBI on acute GVHD after
hematopoietic cell transplantation. Bone Marrow Transplant.
50:559–565. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Valente M, Denis J, Grenier N, Arvers P,
Foucher B, Desangles F, Martigne P, Chaussard H, Drouet M, Abend M
and Hérodin F: Revisiting biomarkers of total-body and partial-body
exposure in a baboon model of irradiation. PLoS One.
10:e01321942015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ringdén O, Ruutu T, Remberger M,
Nikoskelainen J, Volin L, Vindeløv L, Parkkali T, Lenhoff S,
Sallerfors B, Ljungman P, et al: A randomized trial comparing
busulfan with total body irradiation as conditioning in allogeneic
marrow transplant recipients with leukemia: A report from the
Nordic Bone Marrow Transplantation Group. Blood. 83:2723–2730.
1994.PubMed/NCBI
|
|
13
|
Blaise D, Maraninchi D, Michallet M,
Reiffers J, Jouet JP, Milpied N, Devergie A, Attal M, Sotto JJ,
Kuentz M, et al: Long-term follow-up of a randomized trial
comparing the combination of cyclophosphamide with total body
irradiation or busulfan as conditioning regimen for patients
receiving HLA-identical marrow grafts for acute myeloblastic
leukemia in first complete remission. Blood. 97:3669–3671. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dusenbery KE, Daniels KA, McClure JS,
McGlave PB, Ramsay NK, Blazar BR, Neglia JP, Kersey JH and Woods
WG: Randomized comparison of cyclophosphamide-total body
irradiation versus busulfan-cyclophosphamide conditioning in
autologous bone marrow transplantation for acute myeloid leukemia.
Int J Radiat Oncol Biol Phys. 31:119–128. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan
A and Simms S: Randomized trial of busulfan vs total body
irradiation containing conditioning regimens for children with
acute lymphoblastic leukemia: A Pediatric Blood and Marrow
Transplant Consortium study. Bone Marrow Transplant. 32:543–548.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Farese AM, Brown CR, Smith CP, Gibbs AM,
Katz BP, Johnson CS, Prado KL and MacVittie TJ: The ability of
filgrastim to mitigate mortality following LD50/60 total-body
irradiation is administration time-dependent. Health Phys.
106:39–47. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Burnett AF, Biju PG, Lui H and
Hauer-Jensen M: Oral interleukin 11 as a countermeasure to lethal
total-body irradiation in a murine model. Radiat Res. 180:595–602.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nunamaker EA, Anderson RJ, Artwohl JE,
Lyubimov AV and Fortman JD: Predictive observation-based endpoint
criteria for mice receiving total body irradiation. Comp Med.
63:313–322. 2013.PubMed/NCBI
|
|
19
|
Linsenmeier C, Thoennessen D, Negretti L,
Bourquin JP, Streller T, Lütolf UM and Oertel S: Total body
irradiation (TBI) in pediatric patients. A single-center experience
after 30 years of low-dose rate irradiation. Strahlenther Onkol.
186:614–620. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bhatia S, Francisco L, Carter A, Sun CL,
Baker KS, Gurney JG, McGlave PB, Nademanee A, O'Donnell M, Ramsay
NK, et al: Late mortality after allogeneic hematopoietic cell
transplantation and functional status of long-term survivors:
Report from the Bone Marrow Transplant Survivor Study. Blood.
110:3784–3792. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bhatia S, Robison LL, Francisco L, Carter
A, Liu Y, Grant M, Baker KS, Fung H, Gurney JG, McGlave PB, et al:
Late mortality in survivors of autologous hematopoietic-cell
transplantation: Report from the Bone Marrow Transplant Survivor
Study. Blood. 105:4215–4222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Appelbaum FR, Badger CC, Bernstein ID,
Buckner CD, Deeg HJ, Eary JF, Matthews DC, Press OW, Storb R and
Thomas ED: Is there a better way to deliver total body irradiation?
Bone Marrow Transplant. 10 Suppl 1:S77–S81. 1992.
|
|
23
|
Kim JH, Stein A, Tsai N, Schultheiss TE,
Palmer J, Liu A, Rosenthal J, Forman SJ and Wong JY: Extramedullary
relapse following total marrow and lymphoid irradiation in patients
undergoing allogeneic hematopoietic cell transplantation. Int J
Radiat Oncol Biol Phys. 89:75–81. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee KH, Lee JH, Choi SJ, Lee JH, Kim S,
Seol M, Lee YS, Kim WK, Seo EJ, Park CJ, et al: Bone marrow vs
extramedullary relapse of acute leukemia after allogeneic
hematopoietic cell transplantation: Risk factors and clinical
course. Bone Marrow Transplant. 32:835–842. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chong G, Byrnes G, Szer J and Grigg A:
Extramedullary relapse after allogeneic bone marrow transplantation
for haematological malignancy. Bone Marrow Transplant.
26:1011–1015. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Solh M, DeFor TE, Weisdorf DJ and Kaufman
DS: Extramedullary relapse of acute myelogenous leukemia after
allogeneic hematopoietic stem cell transplantation: Better
prognosis than systemic relapse. Biol Blood Marrow Transplant.
18:106–112. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mortimer J, Blinder MA, Schulman S,
Appelbaum FR, Buckner CD, Clift RA, Sanders JE, Storb R and Thomas
ED: Relapse of acute leukemia after marrow transplantation: Natural
history and results of subsequent therapy. J Clin Oncol. 7:50–57.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wong JY, Forman S, Somlo G, Rosenthal J,
Liu A, Schultheiss T, Radany E, Palmer J and Stein A: Dose
escalation of total marrow irradiation with concurrent chemotherapy
in patients with advanced acute leukemia undergoing allogeneic
hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys.
85:148–156. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rosenthal J, Wong J, Stein A, Qian D, Hitt
D, Naeem H, Dagis A, Thomas SH and Forman S: Phase 1/2 trial of
total marrow and lymph node irradiation to augment
reduced-intensity transplantation for advanced hematologic
malignancies. Blood. 117:309–315. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karnofsky DA and Burchenal JH: The
clinical evaluation of chemotherapeutic agents in cancerEvaluation
of Chemotherapeutic Agents. Macleod CM: Columbia University Press;
New York, NY: pp. 1911949
|
|
31
|
Trotti A, Byhardt R, Stetz J, Gwede C,
Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T,
et al: Common toxicity criteria: Version 2.0. an improved reference
for grading the acute effects of cancer treatment: Impact on
radiotherapy. Int J Radiat Oncol Biol Phys. 47:13–47. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
U.S. Department of Health and Human
Services, . The National Institutes of Health and National Cancer
Institute: Common Terminology Criteria for Adverse Events (CTCAE).
Version 4.0.3. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_5×7.pdfJune
14–2010
|
|
33
|
Storek J, Geddes M, Khan F, Huard B, Helg
C, Chalandon Y, Passweg J and Roosnek E: Reconstitution of the
immune system after hematopoietic stem cell transplantation in
humans. Semin Immunopathol. 30:425–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moon SH, Shin KH, Kim TH, Yoon M, Park S,
Lee DH, Kim JW, Kim DW, Park SY and Cho KH: Dosimetric comparison
of four different external beam partial breast irradiation
techniques: Three-dimensional conformal radiotherapy,
intensity-modulated radiotherapy, helical tomotherapy, and proton
beam therapy. Radiother Oncol. 90:66–73. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schultheiss TE, Wong J, Liu A, Olivera G
and Somlo G: Image-guided total marrow and total lymphatic
irradiation using helical tomotherapy. Int J Radiat Oncol Biol
Phys. 67:1259–1267. 2007. View Article : Google Scholar : PubMed/NCBI
|
